FDA recall D-0093-2022

Product

Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01

Reason for recall

Presence of Particulate Matter: Identified as Glass Particles

Distribution

Nationwide within the United States

Key facts

Status

Terminated

Initiation date

2021-10-19

Report date

2021-11-10

Termination date

2023-07-25

Voluntary/Mandated

Voluntary: Firm initiated

Location

Whitehouse Station, NJ, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0093-2022